.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Moodys
Chubb
US Department of Justice
Medtronic
McKesson
Farmers Insurance
Novartis
QuintilesIMS
Chinese Patent Office

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204403

« Back to Dashboard
NDA 204403 describes RIVASTIGMINE, which is a drug marketed by Alvogen Malta, Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, and Alembic Pharms Ltd, and is included in ten NDAs. It is available from one supplier. Additional details are available on the RIVASTIGMINE profile page.

The generic ingredient in RIVASTIGMINE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.

Summary for NDA: 204403

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 204403

Mechanism of ActionCholinesterase Inhibitors

Suppliers and Packaging for NDA: 204403

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIVASTIGMINE
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL 204403 ANDA Alvogen Inc. 47781-304 47781-304-03 30 POUCH in 1 CARTON (47781-304-03) > 1 PATCH, EXTENDED RELEASE in 1 POUCH (47781-304-11)
RIVASTIGMINE
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL 204403 ANDA Alvogen Inc. 47781-305 47781-305-03 30 POUCH in 1 CARTON (47781-305-03) > 1 PATCH, EXTENDED RELEASE in 1 POUCH (47781-305-11)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength4.6MG/24HR
Approval Date:Sep 3, 2015TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength9.5MG/24HR
Approval Date:Sep 3, 2015TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength13.3MG/24HR
Approval Date:Aug 31, 2015TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
QuintilesIMS
Argus Health
UBS
Teva
Baxter
AstraZeneca
Novartis
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot